Evidence-first medicine
These articles separate biological plausibility from human clinical evidence and place benefits alongside risks, uncertainty, and regulatory status.
Clinical perspective
CJC-1295 with DAC, non-DAC modified GRF 1-29, ipamorelin, GH pulses, sleep, proposed benefits, FDA status and evidence gaps explained.
Read the overviewClinical perspective
Explore the biology, human evidence, delivery methods, copper-safety considerations, and compounding standards surrounding GHK Copper.
Read the overviewClinical perspective
An evidence-first comparison of MOTS-c and elamipretide (SS-31): mechanisms, human trial results, the Barth syndrome accelerated approval, and what remains unproven.
Read the overviewClinical perspective
Before starting peptide therapy, learn how evidence, product quality, dosing, storage, monitoring, and clinical oversight affect safety.
Read the overviewClinical perspective
Compare bremelanotide (PT-141), Melanotan I/afamelanotide, and Melanotan II by receptors, approved uses, evidence, risks, and legal status.
Read the overviewClinical perspective
An evidence-first comparison of Selank, Semax, and Epitalon: anxiety, neuroprotection, and circadian-longevity hypotheses, the human evidence, and current FDA compounding status.
Read the overviewClinical perspective
Explore tesamorelin’s randomized human evidence for visceral-fat reduction, emerging liver-fat and body-composition signals, sleep and cognition hypotheses, safety, and responsible medical evaluation.
Read the overview